It is shown that PRSs are unlikely to serve as therapeutic biomarkers but support their use for enhanced risk-stratified prevention and incorporation into clinical models may improve risk stratification and support targeted prevention.
Rachel Delahunty, S. M. Silva, A. Pandey et al.· Cancer Epidemiology, Biomark...· 0 citations
This pooled analysis of 15,731 cases showed that nulliparity, age at menopause, MHT, and BMI have independent, dose-response associations with ER, PR, and grade, clarifying patterns of etiologic heterogeneity.
Daniel Adams, Amber N. Hurson, T. Ahearn et al.· Journal of the National Canc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.